Revance Therapeutics, Inc. (RVNC)
NASDAQ: RVNC · IEX Real-Time Price · USD
2.420
-0.150 (-5.84%)
At close: Jul 2, 2024, 4:00 PM
2.479
+0.059 (2.44%)
After-hours: Jul 2, 2024, 6:27 PM EDT
Revance Therapeutics Stock Forecast
Stock Price Forecast
The 9 analysts with 12-month price forecasts for RVNC stock have an average target of 12, with a low estimate of 8.00 and a high estimate of 20. The average target predicts an increase of 395.87% from the current stock price of 2.42.
Analyst Consensus: Buy
* Price targets were last updated on May 13, 2024.
Analyst Ratings
The average analyst rating for RVNC stock from 9 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Jan '24 | Feb '24 | Mar '24 | Apr '24 | May '24 | Jun '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 3 | 3 | 3 | 3 |
| Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Hold | 4 | 4 | 4 | 4 | 4 | 4 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 9 | 9 | 9 | 9 | 9 | 9 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $12 → $11 | Strong Buy | Maintains | $12 → $11 | +354.55% | May 13, 2024 |
| Goldman Sachs | Goldman Sachs | Hold Maintains $9 → $8 | Hold | Maintains | $9 → $8 | +230.58% | May 13, 2024 |
| Piper Sandler | Piper Sandler | Buy Reiterates $20 → $11 | Buy | Reiterates | $20 → $11 | +354.55% | May 10, 2024 |
| Mizuho | Mizuho | Hold Maintains $9 → $8 | Hold | Maintains | $9 → $8 | +230.58% | May 10, 2024 |
| Needham | Needham | Strong Buy Maintains $18 → $12 | Strong Buy | Maintains | $18 → $12 | +395.87% | May 10, 2024 |
Financial Forecast
Revenue This Year
282.33M
from 234.04M
Increased by 20.63%
Revenue Next Year
380.58M
from 282.33M
Increased by 34.80%
EPS This Year
-2.14
from -3.83
EPS Next Year
-0.90
from -2.14
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 300.9M | 437.3M | 570.8M | 763.9M | 893.8M |
| Avg | 282.3M | 380.6M | 485.3M | 608.0M | 738.9M |
| Low | 262.4M | 332.3M | 399.1M | 471.6M | 549.3M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 28.6% | 54.9% | 50.0% | 57.4% | 47.0% |
| Avg | 20.6% | 34.8% | 27.5% | 25.3% | 21.5% |
| Low | 12.1% | 17.7% | 4.9% | -2.8% | -9.7% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -1.52 | -0.61 | 0.35 | 1.41 | 1.73 |
| Avg | -2.14 | -0.90 | -0.15 | 0.78 | 1.36 |
| Low | -3.32 | -1.27 | -0.74 | 0.44 | 0.94 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | - | 122.5% |
| Avg | - | - | - | - | 75.1% |
| Low | - | - | - | - | 20.8% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.